RxDoctor Payments Data

Sarabjit Kaur

Family · Bakersfield, CANPI 1336778661

Payments from drug & device makers

$697in general payments, 2019–2025

Across 34 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$197
  • Johnson & Johnson$125
  • Lundbeck LLC$52
  • AstraZeneca$45
  • Biosense Webster, Inc.$43
  • Mannkind Corporation$41
  • plus $193 from 9 others

What the payments were for

  • Food & beverage$697100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$697 in reported general payments places this provider in the 65th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$65,906
Medicare patients
175
Services billed
665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$39,951
JardianceEmpagliflozin68$39,818
DapagliflozinDapagliflozin Propanediol54$26,987
LinzessLinaclotide39$23,775
OzempicSemaglutide24$23,493
GocovriAmantadine Hcl14$22,037
Pantoprazole Sodium212$21,304
JanuviaSitagliptin Phosphate38$20,562
Atorvastatin Calcium347$18,913
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$18,097
Alendronate Sodium337$10,954
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,540
JanumetSitagliptin Phos/Metformin Hcl19$10,379
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$8,928
EntrestoSacubitril/Valsartan13$8,506

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere$45$10,54016 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$17$4,13414 claims
Lilly USA, LLCOlanzapine$14$3,03018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,634 family providers in California.

Other family in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →